Anoushka Thoen

Anoushka Thoen

Auto-generated profile, based on publicly available information

Anoushka Thoen

Department of Rehabilitation Sciences, Research Group for Adapted Physical Activity and Psychomotor Rehabilitation, KU Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2021 in Review Journal of Autism and Developmental Disorders
Verified
Journal Article
Closed access
PDF file
ATAnoushka Thoen
Anoushka Thoen
JSJean Steyaert
Jean Steyaert
KAKaat Alaerts
Kaat Alaerts
KEKris Evers
Kris Evers
TDTine Van Damme
Tine Van Damme

15 March 2024 in Applied Psychophysiology and Biofeedback
Verified
Journal Article
Closed access
PDF file
ATAnoushka Thoen
Anoushka Thoen
KAKaat Alaerts
Kaat Alaerts
JPJellina Prinsen
Jellina Prinsen
JSJean Steyaert
Jean Steyaert
TDTine Van Damme
Tine Van Damme

24 April 2023 in Research in Autism Spectrum Disorders
Verified
Journal Article
Closed access
ATAnoushka Thoen
Anoushka Thoen
KAKaat Alaerts
Kaat Alaerts
JSJean Steyaert
Jean Steyaert
SPSophie Pleysier
Sophie Pleysier
TDTine Van Damme
Tine Van Damme

21 October 2021 in Trials
Verified
Journal Article
Open access
PDF file
ATAnoushka Thoen
Anoushka Thoen
JSJean Steyaert
Jean Steyaert
KAKaat Alaerts
Kaat Alaerts
TDTine Van Damme
Tine Van Damme
Background: Prior evidence points towards lower cardiac vagal modulation in individuals with autism spectrum disorder (ASD) as compared to control groups. A cross-sectional phase in this study will gather more evidence concerning this topic. A longitudinal phase will explore the efficacy of a biofeedback intervention based on respiratory sinus arrhythmia (RSA) in adolescents with ASD. Finally, a feasibility study will focus on a non-supervised RSA biofeedback intervention in this population. Methods: The cross-sectional phase includes the comparison of adolescents with ASD (n=38) and age- and gender-matched typically developing peers. A standardized assessment will be used which contains physiological, cortisol, and behavioral measurements. The longitudinal phase contains a randomized, single-blinded, and sham-controlled design to determine the efficacy of supervised RSA biofeedback in adolescents with ASD (n=128). A follow-up phase of 5 weeks is included to evaluate the presence of retention effects. During the latter, a feasibility study will focus on a non-supervised intervention (n=64). Assessments as described previously are scheduled after the intervention and the follow-up phase. Discussion: First, more conclusive evidence will be provided for the presence of lower cardiac vagal modulation in adolescents with ASD as well as the association between these lower values and physiological and behavioral indices. Second, the supervised intervention in adolescents with ASD is hypothesized to upregulate this cardiac vagal modulation and positively change behavioral and physiological parameters. Third, evidence regarding the feasibility and acceptability of a non-supervised intervention may open novel avenues for home-based interventions in this population. Trial registration: ClinicalTrials.gov NCT04628715. Registered on 13 November 2020.

4 June 2023 in medRxiv
Verified
Preprint
Open access
PDF file
ATAnoushka Thoen
Anoushka Thoen
KAKaat Alaerts
Kaat Alaerts
JPJellina Prinsen
Jellina Prinsen
JSJean Steyaert
Jean Steyaert
TDTine Van Damme
Tine Van Damme
Background: Adolescents with autism present lower levels of cardiac vagal modulation in comparison to typically developing peers. These lower values are also associated with psychosocial and behavioral problems. Heart Rate Variability Biofeedback (HRVB) was therefore suggested as an interesting avenue for further exploration since it focusses on the up-regulation of cardiac vagal modulation and has demonstrated positive effects on mental health outcomes. However, scarce evidence was present regarding the effectiveness of HRVB in this population. It was hypothesized that HRVB would increase the level of cardiac vagal modulation in adolescents with autism which would result in positive effects on physiological outcome measures and psychosocial parameters. Furthermore, it was hypothesized that a home-based, non-supervised HRVB training would be feasible in this population. Methods: A single-blind, randomized sham-controlled pilot trial was used. During the initial single-blind phase, adolescents with autism performed supervised HRVB (n=24) or a sham training (n=20) for five weeks with one guided session per week and home-based practice (20 min) on the remaining days. In the subsequent follow-up period of five weeks, half of the adolescents of each group received HRVB training at home, in a non-supervised manner, whereas the other subset did not practice during that period. A combination of physiological, cortisol and behavioral data was collected during standardized stress-provoking assessments before (T0) and after each training period (T1 and T2). Results: Supervised HRVB resulted in a late increase in cardiac vagal modulation in adolescents with autism. Heart rate increased and cortisol decreased significantly immediately after the supervised HRVB training, but none of these effects remained after the follow-up period of five weeks. None of the outcome measures on psychosocial functioning and self-reported stress revealed a significant change following the supervised HRVB training. The home-based HRVB training was feasible in this population but with a significant decrease in compliance rate. However, adolescents reported significantly lower symptoms of stress after this training period, regardless of the prior training (sham or HRVB). Conclusion: HRVB is feasible and effective in adolescents with autism as demonstrated by late-emerging increases in cardiac vagal modulation and less self-reported symptoms of stress. Researchers are encouraged to replicate this study with a larger sample size and to further explore the possible working mechanisms of HRVB.

13 May 2021 in Research Square
Verified
Preprint
Open access
PDF file
ATAnoushka Thoen
Anoushka Thoen
JSJean Steyaert
Jean Steyaert
KAKaat Alaerts
Kaat Alaerts
TDTine Van Damme
Tine Van Damme
Background: Prior evidence points towards lower cardiac vagal modulation in individuals with Autism Spectrum Disorder (ASD) as compared to control groups. A cross-sectional phase in this study will gather more evidence concerning this topic. A longitudinal phase will explore the efficacy of a biofeedback intervention based on Respiratory Sinus Arrhythmia (RSA) in adolescents with ASD. Finally, a feasibility study will focus on a non-supervised RSA biofeedback intervention in this population.Methods: The cross-sectional phase includes the comparison of adolescents with ASD (n=38) and age and gender matched typically developing peers. A standardized assessment will be used which contains physiological, cortisol and behavioral measurements. The longitudinal phase contains a randomized, single-blinded and sham-controlled design to determine the efficacy of supervised RSA biofeedback in adolescents with ASD (n=128). A follow-up phase of 5 weeks is included to evaluate the presence of retention effects. During the latter, a feasibility study will focus on a non-supervised intervention (n=64). Assessments as described previously are scheduled after the intervention and the follow-up phase. Discussion: First, more conclusive evidence will be provided for the presence of lower cardiac vagal modulation in adolescents with ASD as well as the association between these lower values and physiological and behavioral indices. Second, the supervised intervention in adolescents with ASD is hypothesized to upregulate this cardiac vagal modulation and positively change behavioral and physiological parameters. Third, evidence regarding the feasibility and acceptability of a non-supervised intervention may open novel avenues for home-based interventions in this population. Trial registration: ClinicalTrials.gov, NCT04628715. Registered on 13 November 2020. https://clinicaltrials.gov/ct2/show/NCT04628715